Clinical trials: Human Immunodeficiency Virus I Infection
Cytomegalovirus Infections, HIV Infections
A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection
To evaluate the clinical and laboratory toxicity of ganciclovir (GCV) and zidovudine (AZT) when given in combination. Because recent information has shown AZT to be useful in treating AIDS, it is assumed that most patients with…
- Trial name
- NCT00000995
- Testing
- Zidovudine, Ganciclovir
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Microbiota Restoration Therapy in HIV With Repeated Low-Dose Interventions
Altered interplay between gut mucosa and dysbiotic bacteria during HIV infection seems to contribute to chronic immune dysfunction.
- Trial name
- REFRESH (NCT03008941)
- Testing
- FMT
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
HIV Infection
Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together
The aim of the study is to see if apricitabine or tipranavir affect the levels of each other in the blood (pharmacokinetic interaction) when they are dosed together.
- Trial name
- NCT00352066
- Testing
- apricitabine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Avexa
HIV Infections, TB
A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both
This study is designed to evaluate the safety of MVA85A in asymptomatic volunteers in South Africa who are infected with M.tb, HIV or both.
- Trial name
- NCT00480558
- Testing
- MVA 85A
- Where
- South Africa
- Volunteers
- 48 people
- Sponsor
- University of Oxford
Immune Thrombocytopenic Purpura ( ITP ), HIV Infections
A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura
To test the effectiveness of recombinant human CD4 Immunoglobulin G (CD4-IgG) in the treatment of HIV-associated immune thrombocytopenic purpura in patients with all levels of HIV infection.
- Trial name
- NCT00002250
- Testing
- CD4-IgG
- Where
- United States
- Sponsor
- Genentech, Inc.
Human Immunodeficiency Virus I Infection, Drug Use
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed
In an effort to engage more HIV-infected PWUD into care, and ensure treatment adherence and efficacy, simplification of older, multi-tablet regimens is required.
- Trial name
- NCT04132674
- Testing
- Bictegravir/emtricitabine/tenofovir alafenamide
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Vancouver Infectious Diseases Centre
Infection, Human Immunodeficiency Virus I
ZIAGEN® Post-marketing Surveillance
An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and efficacy of ZIAGEN® administered in Korean patients according to the prescribing information.
- Trial name
- NCT01205243
- Testing
- ZIAGEN®
- Where
- South Korea
- Volunteers
- 671 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.
To study the safety and toxicity of intranasal peptide T (D-Ala-1-peptide-T-amide) in humans, and to find out how quickly and how much of a given dose enters the bloodstream and how quickly it leaves the bloodstream.
- Trial name
- NCT00000391
- Testing
- Peptide T
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Mental Health (NIMH)
Healthy
Vaccine Treatment for HIV-Infection
This study will determine the safety and side effects of an experimental adenoviral vector vaccine given to patients who previously received a different HIV vaccine (VRC-HIVDNA016-00-VP) in a prior NIAID study.
- Trial name
- NCT00108654
- Testing
- VRC-HIVADV014-00-VP
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV -1 Infection
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
This study will test the safety and blood levels of the antibody BNT351 in people living without and with human immunodeficiency virus (HIV).
- Trial name
- NCT07392372
- Testing
- BNT351
- Where
- 6 sites in United States, Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
HIV Infections
A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection
To determine the safety and immunogenicity of gp160 (MicroGeneSys), rgp120/HIV-1MN (Genentech), and rgp120/HIV-1SF2 (BIOCINE) and their adjuvants in HIV-infected children 1 month to 18 years of age.
- Trial name
- NCT00000762
- Testing
- rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys)
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus
Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
GSK has in-licensed a novel NNRTI-class candidate (GSK2248761, IDX12899) for the treatment of subjects with HIV-1 infection from Idenix Pharmaceuticals.
- Trial name
- NCT00945282
- Testing
- GSK2248761, Lopinavir/ritonavir, HAART
- Where
- Argentina
- Volunteers
- 8 people
- Sponsor
- ViiV Healthcare
HIV-1-infection, HIV Infections
A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA
The purpose of this study is to evaluate the efficacy and safety of CABENUVA (Long-acting Cabotegravir Plus Long-acting Rilpivirine) in patients with HIV infection and severe renal impairment.
- Conditions
- HIV-1-infection, HIV Infections, HIV I Infection
- Trial name
- CAPRI (NCT05601128)
- Testing
- CAB + RPV
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
HIV Infections
A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection
AMENDED: As of 10/19/90 only Children 0 to 3 months are being enrolled. Original design: To determine whether the experimental drug recombinant CD4 (rCD4), which is produced through genetic engineering technology, is safe and…
- Trial name
- NCT00000984
- Testing
- CD4 Antigens
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HTLV-I Infection, Tropical Spastic Paraparesis
Evaluation of Patients With HAM/TSP
Objective: Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) is a rare neurologic disorder that affects less than 5% of patients infected with the HTLV-I virus.
- Trial name
- NCT00001778
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HIV-1 Infection
The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART
The purpose of this study is to compare HIV RNA expression and infection within resting (CD4)+ cells in HIV-infected patients on stable ART before and after a single exposure to Vorinostat (VOR), after exposure to short intervals…
- Trial name
- NCT01319383
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of North Carolina, Chapel Hill
Lymphoproliferation Induced by HTLV-1, HTLV-1 Adult T-cell Lymphoma / Leukemia
Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)
The purpose of this study is to evaluate the outcome (survival) of Adult T-cell leukemia / lymphoma (ATL) patients who receive or not specific treatment for their hemopathy (cohort 1) and the outcome (survival) of HTLV-1…
- Conditions
- Lymphoproliferation Induced by HTLV-1, HTLV-1 Adult T-cell Lymphoma / Leukemia, HTLV-1 Infection
- Trial name
- HTLV-OBS (NCT05237245)
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infections, Cytopenias
A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility
To assess the safety and efficacy of subcutaneously administered sargramostim ( granulocyte-macrophage colony-stimulating factor; GM-CSF ) in increasing and maintaining the neutrophil count in HIV-infected adults who have…
- Trial name
- NCT00002006
- Testing
- Zidovudine, Sargramostim
- Where
- United States
- Sponsor
- Sandoz
Infection, Human Immunodeficiency Virus
Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects
This study will be a phase 1, open label, parallel group, three period crossover study to evaluate the effect of dolutegravir (DTG) on the steady state pharmacokinetics of metformin and on the safety and tolerability of…
- Trial name
- NCT02064374
- Testing
- Metformin 500 mg q12h, Dolutegravir 50 mg q24h, Dolutegravir 50 mg q12h
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV-1-infection
Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy
An Open-Label Study to Evaluate Switching from a Regimen of Elvitegravir/Tenofovir alafenamide/Emtricitabine/Cobicistat and Darunavir, to a Fixed-Dose Combination of Bictegravir/Tenofovir alafenamide/Emtricitabine in…
- Trial name
- NCT04040075
- Testing
- Biktarvy Tab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Southampton Healthcare, Inc.